Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free survival compared to Merck's Keytruda, despite showing numerically longer median survival with the high-dose combination. No new safety issues were found. The trial involved 1,546 patients with advanced melanoma and compared two dose levels of fianlimab plus cemiplimab against pembrolizumab. Meanwhile, Regeneron recently partnered with Telix Pharmaceuticals to develop new radiopharmaceutical therapies in oncology, aiming to strengthen their market position.
Regeneron Pharmaceuticals has entered a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs), a novel therapy class aimed at difficult-to-treat targets. Regeneron will invest $125 million upfront and potenti...
Regeneron's Phase 3 trial testing fianlimab (LAG-3 inhibitor) combined with cemiplimab (PD-1 inhibitor) as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of improved prog...
At the 2026 Regeneron International Science and Engineering Fair, over $7 million in awards were given to more than 1,700 young STEM students from 67+ countries. Hikaru Kuribayashi, 17, won the top $100,000 prize for his simulation program predicting...
The 2026 Regeneron International Science and Engineering Fair awarded more than $7 million to over 1,700 young STEM finalists from 67+ countries. Hikaru Kuribayashi won the top $100,000 George D. Yancopoulos Innovator Award for creating a simulation ...
